Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

RPRX vs. AMGN: Which Stock Is the Better Value Option?

📊 Both Royalty Pharma (RPRX) and Amgen (AMGN) are highlighted as options within the Medical-Biomedical and Genetics sectors.

🏆 Zacks Investment Research evaluates stocks by pairing Style Scores with their Zacks Rank to identify value opportunities.

💼 Royalty Pharma currently holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook revision.

⚖️ Amgen holds a Zacks Rank of #3 (Hold), reflecting a more neutral stance on its recent earnings estimates.

📉 RPRX has a forward Price-to-Earnings (P/E) ratio of 9.92, significantly lower than AMGN's 14.84.

🧮 The PEG ratio for RPRX is 3.22, while AMGN’s stands slightly higher at 3.35.

📚 Royalty Pharma has a Price-to-Book (P/B) ratio of 3 compared to Amgen's much higher 19.35.

🏅 These valuation metrics contribute to RPRX receiving a "B" grade in the Value category of Style Scores.

⚠️ Amgen currently holds a "C" grade in the Value category due to its higher relative valuations.

📈 Analysts conclude that RPRX is likely the superior value option based on these combined metrics and rankings.

📄 Free stock analysis reports are available for both companies via Zacks Investment Research.

Bullish Signals
  • Amgen currently holds a Zacks Rank of #3 (Hold), indicating a neutral-to-positive earnings estimate trajectory for the pharmaceutical giant.
  • The analysis notes that Amgen has a forward P/E ratio of 14.84, which provides a valuation metric for investors to consider alongside its cash flow and book value per share.
  • With a Value grade of C from the Style Scores system, Amgen is identified as an undervalued company by key metrics including earnings yield and cash flow per share.
Risk Factors
  • Amgen has been assigned a 'Hold' rating with a Zacks Rank of #3, suggesting analysts are cautious about its recent earnings estimates and outlook.
  • Amgen received a lower Value grade of C compared to Royalty Pharma's B grade, indicating it may be less attractive to value investors based on traditional metrics like P/E ratio and earnings yield.
  • The company's forward P/B ratio of 19.35 is significantly higher than Royalty Pharma's 3.0, which could signal that the market perceives Amgen as less undervalued relative to its book value.
  • Amgen has a higher PEG ratio of 3.35 compared to Royalty Pharma's 3.22, potentially reflecting slower expected earnings growth or higher valuation multiples that warrant scrutiny.
Full Analysis
Amgen Inc. (AMGN) is being compared with Royalty Pharma (RPRX) in an analysis from Zacks Investment Research to determine which stock represents the better value option for investors interested in the Medical-Biomedical and Genetics sectors. The article utilizes Zacks Rank and Style Scores, specifically focusing on Value metrics, to evaluate both companies. Regarding earnings estimates, RPRX holds a Zacks Rank of #2 (Buy), indicating a stronger recent improvement to its earnings outlook, whereas AMGN currently holds a Zacks Rank of #3 (Hold). The analysis highlights specific valuation differences between the two stocks using traditional financial metrics. Royalty Pharma is assigned a forward Price-to-Earnings (P/E) ratio of 9.92 and a PEG ratio of 3.22, while Amgen trades at a forward P/E of 14.84 with a PEG ratio of 3.35. Additionally, RPRX has a significantly lower Price-to-Book (P/B) ratio of 3 compared to Amgen's much higher P/B ratio of 19.35. These valuation metrics contribute to RPRX receiving a "B" grade in the Value category from Zacks' Style Scores system, while AMGN receives a "C" grade based on its current share price and fundamentals. The article concludes that because RPRX combines an improving earnings outlook with superior traditional value metrics, it is currently viewed as the more attractive value option than Amgen. The text also includes references to downloading free stock analysis reports for both Royalty Pharma and Amgen from Zacks Investment Research, alongside standard website navigation elements like a portfolio sign-in prompt.